Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) and Exagen (NASDAQ:XGN – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.
Volatility and Risk
Fresenius Medical Care AG & Co. KGaA has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Exagen has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500.
Profitability
This table compares Fresenius Medical Care AG & Co. KGaA and Exagen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fresenius Medical Care AG & Co. KGaA | 4.83% | 9.28% | 4.16% |
| Exagen | -26.61% | -104.46% | -28.93% |
Earnings and Valuation
This table compares Fresenius Medical Care AG & Co. KGaA and Exagen”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fresenius Medical Care AG & Co. KGaA | $22.20 billion | 0.56 | $1.11 billion | $1.73 | 13.52 |
| Exagen | $66.57 million | 2.11 | -$19.95 million | ($0.81) | -7.17 |
Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Fresenius Medical Care AG & Co. KGaA and Exagen, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresenius Medical Care AG & Co. KGaA | 4 | 7 | 0 | 0 | 1.64 |
| Exagen | 1 | 0 | 7 | 1 | 2.89 |
Fresenius Medical Care AG & Co. KGaA currently has a consensus target price of $23.42, indicating a potential upside of 0.17%. Exagen has a consensus target price of $10.12, indicating a potential upside of 74.27%. Given Exagen’s stronger consensus rating and higher probable upside, analysts plainly believe Exagen is more favorable than Fresenius Medical Care AG & Co. KGaA.
Insider and Institutional Ownership
8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. Comparatively, 75.2% of Exagen shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Exagen beats Fresenius Medical Care AG & Co. KGaA on 8 of the 14 factors compared between the two stocks.
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
About Exagen
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
